Clinical Trial Results:
A Randomized Multi-center Open Label Study of BMS-354825 vs.
Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia
Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant
to Imatinib at a Dose at 400 - 600 mg/d
Summary
|
|
EudraCT number |
2004-004450-96 |
Trial protocol |
AT SE DE HU FI GB IE DK EE ES BE |
Global completion date |
20 Nov 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-017_Synopsis_Final CA180-017_Synopsis_Interim |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.